Yizhen Fu
Overview
Explore the profile of Yizhen Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu Y, Zhang Y, Hu D, Zhou Z, Xu L, Chen M
J Clin Oncol
. 2025 Feb;
:JCO2402615.
PMID: 39999399
No abstract available.
2.
Zhang Y, Chen J, Zhou Z, Hu D, Wang J, Pan Y, et al.
Radiology
. 2025 Feb;
314(2):e241096.
PMID: 39903071
Background Radiofrequency ablation (RFA) has comparable clinical outcomes to surgical resection (SR) for treating small recurrent hepatocellular carcinoma (HCC). However, whether combined transarterial chemoembolization (TACE) with RFA (hereafter, TACE-RFA) outperforms...
3.
Yang Z, Wang X, Fu Y, Wu W, Hu Z, Lin Q, et al.
Mol Cancer
. 2025 Jan;
24(1):39.
PMID: 39891255
No abstract available.
4.
He M, Xie W, Yuan Z, Chen J, Wang J, Fu Y, et al.
Int J Cancer
. 2025 Jan;
PMID: 39834172
With the rise of anti-vascular endothelial growth factor antibody and programmed cell death-ligand 1 (PD-L1) regimens, particularly bevacizumab and atezolizumab, as first-line treatments for advanced hepatocellular carcinoma (HCC), there is...
5.
Yang Z, Wang Q, Hu L, Sima X, Wang J, Hu D, et al.
Front Immunol
. 2025 Jan;
15:1469302.
PMID: 39763684
Background: Transarterial therapy (TAT), bevacizumab (Bev), and immune checkpoint inhibitors (ICIs) have individually exhibited efficacy in treating advanced-stage hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety...
6.
Xi M, Yang Z, Hu L, Fu Y, Hu D, Zhou Z, et al.
J Clin Oncol
. 2024 Dec;
43(9):1073-1082.
PMID: 39693584
Purpose: To assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC). Methods: In this trial, patients with recurrent...
7.
Yang Z, Wu W, Hu Z, Fu Y, Hu Z, Pan Y, et al.
Front Immunol
. 2024 Dec;
15:1494520.
PMID: 39676872
Background: Systemic chemotherapy (SC) stands the only first-line treatment for advanced intrahepatic cholangiocarcinoma (iCCA) for the past few decades. Immune checkpoint inhibitors (ICIs) have been proved to provide additional benefit...
8.
Hu Z, Yang Z, Fu Z, Fu Y, Ma Z, Zhou Z, et al.
Front Immunol
. 2024 Dec;
15:1472870.
PMID: 39628474
Background: The relative superiority of atezolizumab-bevacizumab versus pembrolizumab-lenvatinib in treatment of unresectable hepatocellular carcinoma (HCC) remains uncertain. This study aims to compare the efficacy of atezolizumab-bevacizumab and pembrolizumab-lenvatinib in first-line...
9.
Hu L, Yang Z, Yang Z, Peng W, Tang X, Ye Z, et al.
Hepatol Int
. 2024 Dec;
PMID: 39621230
Background: Regorafenib is the recommended second-line therapy for unresectable hepatocellular carcinoma (uHCC). Our study aimed to assess the effect of transition timing to second-line therapy with regorafenib on treatment outcomes...
10.
Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z, et al.
Immunotargets Ther
. 2024 Oct;
13:559-569.
PMID: 39478940
Objection: To report the efficacy and safety of triple combination therapy with bevacizumab plus anti-PD-1 (BP1) or anti-PD-L1 inhibitors (BPL) combined with hepatic arterial infusion chemotherapy (HAIC) as a first-line...